Cytovation Overview

  • Founded
  • 2001
Founded
  • Status
  • Private
  • Employees
  • 5
Employees
  • Latest Deal Type
  • Series 1
  • Investors
  • 1

Cytovation General Information

Description

Developer of synthetic peptides designed to provide treatment of benign skin tumors and different types of cancer. The company develops CyPep-1 peptide with a novel mechanism of action that guides the immune system to recognize and eradicate tumours, enabling patients to get treatment of cutaneous warts and malignant cancers.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Pharmaceuticals
Primary Office
  • Møllendalsveien 65 C
  • 5009 Bergen
  • Norway
+47 55 00 00 00

Cytovation Timeline

2018201920202021
Financing RoundFinancing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Cytovation Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Later Stage VC (Series 1) 01-Jan-2019 00.000 Completed Clinical Trials - Phase 1
1. Angel (individual) 08-Jan-2018 00.000 00.000 Completed Clinical Trials - Phase 1
To view Cytovation’s complete valuation and funding history, request access »

Cytovation Patents

Cytovation Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
CA-3103905-A1 Combination therapy using a peptide Pending 19-Jun-2018 00000000000
AU-2019291079-A1 Combination therapy using a peptide Pending 19-Jun-2018 00000000000
GB-201810058-D0 Combination therapy using a peptide Ceased 19-Jun-2018 000000000
EP-3810279-A1 Combination therapy using a peptide Pending 19-Jun-2018 00000000000
US-20210154268-A1 Combination therapy using a peptide Pending 19-Jun-2018 A61K38/16

Cytovation Executive Team (4)

Name Title Board Seat Contact Info
Lars Prestegarden MD Co-Founder, Chief Executive Officer and Chief Scientific Officer
Kjell-Inge Arnevig Chief Operating Officer
Federico Grego Chief Business Officer
Per Lønning Ph.D Co-Founder and Chairman
To view Cytovation’s complete executive team members history, request access »

Cytovation Board Members (4)

Name Representing Role Since
Egil Sjursen Cytovation Board Member 000 0000
Per Lønning Ph.D Cytovation Co-Founder and Chairman 000 0000
Rolf Bjerkvig Ph.D Cytovation Board Member 000 0000
Stein Mohn Ph.D Cytovation Board Member 000 0000
To view Cytovation’s complete board members history, request access »

Cytovation Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Cytovation Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Sandwater Venture Capital Minority 000 0000 000000 0
To view Cytovation’s complete investors history, request access »